Hookipa Pharma Inc. HOOK
We take great care to ensure that the data presented and summarized in this overview for HOOKIPA Pharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HOOK
View all-
Baker Bros. Advisors LP New York, NY8.13MShares$6.01 Million0.07% of portfolio
-
Artal Group S.A. Luxembourg, N45.67MShares$4.19 Million0.22% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.52MShares$4.08 Million2.45% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.6MShares$3.4 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.12MShares$1.57 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.24MShares$917,6530.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.06MShares$787,1890.03% of portfolio
-
Acadian Asset Management LLC Boston, MA882KShares$652,8730.0% of portfolio
-
Geode Capital Management, LLC Boston, MA665KShares$491,8110.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX531KShares$392,7740.05% of portfolio
Latest Institutional Activity in HOOK
Top Purchases
Top Sells
About HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Insider Transactions at HOOK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2023
|
Reinhard Kandera Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,000
+13.97%
|
$0
$0.72 P/Share
|
|
Aug 16
2023
|
Reinhard Kandera Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+18.14%
|
$0
$0.71 P/Share
|
|
Jul 11
2023
|
Jorn Aldag Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+6.5%
|
$0
$0.83 P/Share
|
|
Jul 07
2023
|
Jorn Aldag Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+6.95%
|
$0
$0.81 P/Share
|
|
Jul 05
2023
|
Jorn Aldag Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+7.47%
|
$0
$0.89 P/Share
|
|
Jul 03
2023
|
Jorn Aldag Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+8.07%
|
$0
$0.89 P/Share
|
|
Jun 30
2023
|
Reinhard Kandera Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+29.93%
|
$0
$0.88 P/Share
|
|
Feb 01
2022
|
Jorn Aldag Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,824
+47.93%
|
$143,472
$3.0 P/Share
|
|
Feb 01
2022
|
Reinhard Kandera Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,056
+46.62%
|
$42,168
$3.0 P/Share
|
|
Feb 01
2022
|
Igor Matushansky Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,933
+12.97%
|
$44,799
$3.0 P/Share
|
|
Feb 01
2022
|
Roman Necina Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,892
+46.43%
|
$38,676
$3.0 P/Share
|
|
Feb 01
2022
|
Christine D. Baker Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,658
+45.81%
|
$40,974
$3.0 P/Share
|
|
Feb 01
2022
|
Klaus Orlinger Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,188
+46.9%
|
$27,564
$3.0 P/Share
|
|
Dec 21
2021
|
Igor Matushansky Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,949
-5.62%
|
$29,898
$2.49 P/Share
|
|
Dec 21
2021
|
Igor Matushansky Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,853
+7.81%
|
$0
$0.1 P/Share
|
|
Apr 21
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
328,620
-9.37%
|
$3,614,820
$11.6 P/Share
|
|
Mar 29
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
36,829
-1.04%
|
$478,777
$13.67 P/Share
|
|
Mar 26
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
35,171
-0.98%
|
$457,223
$13.69 P/Share
|
|
Mar 25
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
28,546
-0.79%
|
$371,098
$13.12 P/Share
|
|
Mar 24
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
52,690
-1.44%
|
$684,970
$13.7 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 47K shares |
|---|